243 related articles for article (PubMed ID: 30918101)
1. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Csikós J; Cairney CJ; Blitzer A
Neurology; 2019 Apr; 92(17):e1982-e1991. PubMed ID: 30918101
[TBL] [Abstract][Full Text] [Related]
2. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Dorsch U; Csikós J; Blitzer A
Parkinsonism Relat Disord; 2020 Jan; 70():23-30. PubMed ID: 31794936
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial.
Isaacson SH; Ondo W; Jackson CE; Trosch RM; Molho E; Pagan F; Lew M; Dashtipour K; Clinch T; Espay AJ;
JAMA Neurol; 2020 Apr; 77(4):461-469. PubMed ID: 31930364
[TBL] [Abstract][Full Text] [Related]
4. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients.
Jost WH; Steffen A; Berweck S
Expert Rev Neurother; 2021 Oct; 21(10):1059-1068. PubMed ID: 34516331
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE).
Masakado Y; Abo M; Kondo K; Saeki S; Saitoh E; Dekundy A; Hanschmann A; Kaji R;
J Neurol; 2020 Jul; 267(7):2029-2041. PubMed ID: 32219557
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
[TBL] [Abstract][Full Text] [Related]
7. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
Berweck S; Bonikowski M; Kim H; Althaus M; Flatau-Baqué B; Mueller D; Banach MD
Neurology; 2021 Oct; 97(14):e1425-e1436. PubMed ID: 34341153
[TBL] [Abstract][Full Text] [Related]
8. IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study.
Marciniak C; Munin MC; Brashear A; Rubin BS; Patel AT; Slawek J; Hanschmann A; Hiersemenzel R; Elovic EP
Adv Ther; 2019 Jan; 36(1):187-199. PubMed ID: 30484117
[TBL] [Abstract][Full Text] [Related]
9. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity.
Elovic EP; Munin MC; Kaňovský P; Hanschmann A; Hiersemenzel R; Marciniak C
Muscle Nerve; 2016 Mar; 53(3):415-21. PubMed ID: 26201835
[TBL] [Abstract][Full Text] [Related]
10. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
Ondo WG; Hunter C; Moore W
Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
Jankovic J; Comella C; Hanschmann A; Grafe S
Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
[TBL] [Abstract][Full Text] [Related]
13. Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis.
Berweck S; Banach M; Gaebler-Spira D; Chambers HG; Schroeder AS; Geister TL; Althaus M; Hanschmann A; Vacchelli M; Bonfert MV; Heinen F; Dabrowski E
Toxins (Basel); 2022 Aug; 14(9):. PubMed ID: 36136523
[TBL] [Abstract][Full Text] [Related]
14. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial.
Arbouw ME; Movig KL; Koopmann M; Poels PJ; Guchelaar HJ; Egberts TC; Neef C; van Vugt JP
Neurology; 2010 Apr; 74(15):1203-7. PubMed ID: 20385892
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study.
Jog M; Lee J; Scheschonka A; Chen R; Ismail F; Boulias C; Hobson D; King D; Althaus M; Simon O; Dersch H; Frucht S; Simpson DM
Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33419261
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
Evidente VG; Fernandez HH; LeDoux MS; Brashear A; Grafe S; Hanschmann A; Comella CL
J Neural Transm (Vienna); 2013 Dec; 120(12):1699-707. PubMed ID: 23779062
[TBL] [Abstract][Full Text] [Related]
17. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.
Mitsikostas DD; Dekundy A; Sternberg K; Althaus M; Pagan F
Adv Ther; 2020 Oct; 37(10):4249-4265. PubMed ID: 32779096
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
Jost WH; Benecke R; Hauschke D; Jankovic J; Kaňovský P; Roggenkämper P; Simpson DM; Comella CL
Drug Des Devel Ther; 2015; 9():1913-26. PubMed ID: 25897202
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of botulinum toxin A for treatment of drooling.
Lipp A; Trottenberg T; Schink T; Kupsch A; Arnold G
Neurology; 2003 Nov; 61(9):1279-81. PubMed ID: 14610139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
